|
Phase II Intravenous Administration Melanoma Trial - United States
In August 2008, Oncolytics announced that the U.S. National Cancer Institute had started enrolment in a Phase II trial for patients with metastatic melanoma using systemic administration of REOLYSIN®. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN®.
See related press releases and documents:
August 12, 2008 - U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN®
May 14, 2007 - U.S. NCI Files for Phase II Systemic Melanoma Clinical Trial with REOLYSIN®
January 18, 2006 - Oncolytics Biotech Inc. Announces Commencement of Solicitation Process for Clinical Trials Sponsored by the U.S. National Cancer Institute
October 29, 2003 - Oncolytics Biotech Inc. and the U.S. National Cancer Institute to Collaborate on Multiple Clinical Trials with REOLYSIN®
|
